All News
ACR 2025 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
Read Article
Bone Density in Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a burden on the bones—both literally and diagnostically. The disease’s dual nature, marked by chronic inflammation and abnormal new bone formation, complicates the assessment of bone health.
Read Article
Tofacitinib in AxSpA in Developing Countries
Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at #ACR25
https://t.co/4kTv90PhIC https://t.co/WRUBP0O21b
Links:
Dr. John Cush RheumNow ( View Tweet)
Difficult to Manage axSpA
Drs. Antoni Chan and Rodrigo Garcia Salinas discuss abstract 0584, "Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns", presented at #ACR25 https://t.co/84HZojI3FJ
Dr. John Cush RheumNow ( View Tweet)
Early Peripheral SpA: Is it okay to stop treatment sometimes?
Dr. Richard Conway reports on abstract 0568 "Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial," presented at #ACR25
https://t.co/FtI2o90v9O https://t.co/jUAEDZhDW5
Dr. John Cush RheumNow ( View Tweet)
Catching AxSpA Early: Closing the Diagnostic Gap
Dr. Akhil Sood reports on abstract 2635 and abstract 2636 presented at #ACR25.
https://t.co/TmJQKQUu9E https://t.co/6dWf8DY2W3
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3
Dr. John Cush RheumNow ( View Tweet)
💬 #ACR2025 Topic Panels — LIVE!
Nov. 2 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 PsA
Join Us Live on:
X Live • Facebook Live • YouTube Live • LinkedIn Live • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss https://t.co/A4pUjZG3Dr
Links:
Dr. John Cush RheumNow ( View Tweet)
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases
At #ACR25, the ACR presented new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, https://t.co/nJjtTMHnD3
Dr. John Cush RheumNow ( View Tweet)
What happens if you have #axSpA & concomitant #FM?
Pts with both have less TNFi retention,
-residual pain may lead to d/c Rx.
Need to determine if axSpA pt has #fibromyalgia as there may not be objective findings if no peripheral arthritis in axSpA.
#ACR25 @RheumNow abst#534
Janet Pope Janetbirdope ( View Tweet)
In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespiratory fitness ( increased oxygen pulse, ventilatory efficiency, anaerobic threshold). BASDAI and chest expansion also improved. Supports tailored rehab based on https://t.co/jawosa2AJK
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In early axSpA vs non-axSpA CBP, 2 year spinal x-ray progression was minimal in both groups. But on MRI, fat lesions increased significantly in axSpA (0.16 units/yr vs –0.02), with 15% having ≥3 lesions at 2 year vs 1% in non-axSpA. Fat lesions may signal early structural https://t.co/zvgU1Gt0po
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
New biomarkers in axSpA. In early axSpA (DESIR cohort), higher baseline Phospholipid transfer protein (PLTP) activity was linked to sacroiliac radiographic progression over 5 years. Lower zonulin and lipopolysaccharides (LPS) levels also associated with progression. Highlights https://t.co/1uBtR4QA97
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Clinical Year in Preview
SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps
@RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz
Jiha Lee JihaRheum ( View Tweet)
In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Use of AI in AxSpA imaging for diagnosis. ASembleNet, a hybrid deep learning model, achieved 99% accuracy on coronal and 98.1% on axial MRI for AS classification, outcomes higher than ResNet50, Xception, and InceptionV3. Validated on ASAS cases, with Grad-CAM interpretability and https://t.co/yU8shaIdP2
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
What's the latest in PsA? https://t.co/I8ZgRQpVy6
Great review for whats new in PsA by @drpnash
Looking forward for Large IL23-Axial study results.
@RheumNow
#ACR25
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts
JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04)
Individualize tx. consider potential complications
#ACR25 @RheumNow Abs2633 https://t.co/pjKAazQFwW
Links:
sheila RHEUMarampa ( View Tweet)
Sex differences in 💊 d/c in axSpA from the RISE registry
🔅Females - ⬆️discontinuation risks for TNFi
🔅No sex differences seen in dc risks for IL17i and JAKis
🔅Young females discontinued faster than males
Gender diff in SpA can guide tx decisions
#ACR25 @RheumNow Abs2634 https://t.co/kcXfZrU4zI
Links:
sheila RHEUMarampa ( View Tweet)
In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleeding vs TNFi, but lower malignancy risk. Infection rates were similar, with a trend toward more herpes zoster in JAKi users. Abstract#2633 @RheumNow #ACR25 https://t.co/pPY0wpAKA3
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
